These antibodies may also be very useful for reducing platelet-tumor cell interactions and reducing tumor metastasis. At therapeutic doses, the humanized antibody lacks the activity of inducing platelet activation, inducing thrombocytopenia and/or prolonging bleeding time....
(JON1, JON2, and JON3) that induce thrombocytopeniawere sensitive to IVIG treatment, which is consistent with earlierstudies using other monoclonal antibodies against GPIIbIIIa.Also, JON2 was unable to induce thrombocytopenia in FcRchain/ mice, confirming that this anti-GPIIbIIIa antibodyis FcR-...